Aureon Laboratories Announces Appointment of New CEO

Robert Shovlin Promoted From President to President and CEO

        Print
| Source: Aureon Laboratories, Inc.

YONKERS, N.Y., Aug. 25, 2009 (GLOBE NEWSWIRE) -- Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced the promotion of Robert Shovlin from the company's President to President and Chief Executive Officer. Vijay Aggarwal, PhD will step down as CEO, but will remain a member of the company's board of directors. Dr. Aggarwal will also remain actively involved in shaping the company's long-term strategies as Aureon continues its evolution.

"Since launching our prognostic tests for prostate cancer last year, our company has enjoyed rapid growth and expansion," said Kevin Johnson, Chairman of Aureon Laboratories. "Rob has played a central role in leading the company and driving our success. We are excited about the company's future trajectory and for what we will accomplish under Rob's direction."

Commenting on the transition, Mr. Shovlin said "Vijay's leadership and dedication have been instrumental in building Aureon into the company it is today. I am excited to be given the added responsibility of CEO and will continue to work closely with Vijay as we build upon the strong foundation we have established and expand the applications of our proprietary technology."

Robert Shovlin joined Aureon Laboratories in June of 2005 as Vice President of Sales and Marketing and was subsequently promoted to Chief Operating Officer in 2007 then President and COO in 2008. As President and COO, Mr. Shovlin led the company's research and development, sales and product management activities. In addition, he played a leading role in the 2008 commercial launch of the company's prognostic test Prostate Px+. Prostate Px+ helps newly diagnosed patients make more informed treatment decisions by providing an objective and personalized analysis of the patient's cancer from the molecular level. Prostate Px+ successfully identifies patients with aggressive, life-threatening prostate cancer with greater accuracy than any other method currently available.

Prior to joining Aureon, Mr. Shovlin was the Executive Director of Anatomic Pathology for Quest Diagnostics Incorporated (NYSE:DGX). Mr. Shovlin also previously held various sales and sales management roles at DIANON Systems, Inc. He is a former Captain in the United States Marine Corps who holds a B.S. from Penn State University and an M.B.A. from Rutgers University.

The Aureon Laboratories logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6360

About Aureon Laboratories

Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit www.aureon.com or call 1-888-SYS-PATH.

Aureon Laboratories
Jason Alter, Ph.D.
914-377-4036